Question 1

What is Ovid Therapeutics's P/E ratio?

Accepted Answer

Ovid Therapeutics (OVID) P/E ratio is 1.6× as of May 9, 2022. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Ovid Therapeutics?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Ovid Therapeutics specifically, the relevant sector benchmark is the current sector median of 25.0×.

Question 5

Is Ovid Therapeutics's P/E ratio high or low?

Accepted Answer

Ovid Therapeutics's P/E ratio of 1.6× is below its own 5-year average of 1.9× and below the sector median of 25.0×. That places the current reading at the 6th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Ovid Therapeutics's historical P/E ratio range?

Accepted Answer

In the available daily series, Ovid Therapeutics (OVID) P/E ratio has ranged from a low of 1.4× in 2022 to a high of 2.6× in 2021. The 5-year average is 1.9× and the 5-year median is 1.8×.

Question 7

What was Ovid Therapeutics's P/E ratio in 2021?

Accepted Answer

Ovid Therapeutics (OVID) P/E ratio at the end of 2021 was 1.8×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Ovid Therapeutics's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$133.12M	−$17.41M	—	—	Dec 31, 2025
2024	$66.30M	−$26.43M	—	—	Dec 31, 2024
2023	$227.61M	−$52.34M	—	—	Dec 31, 2023
2022	$131.08M	−$54.17M	—	—	Dec 31, 2022
2021	$216.70M	$123.68M	1.8×	—	Dec 31, 2021
2020	$145.42M	−$81.04M	—	—	Dec 31, 2020
2019	$203.94M	−$60.46M	—	—	Dec 31, 2019
2018	$59.62M	−$51.98M	—	—	Dec 31, 2018
2017	$242.86M	−$64.81M	—	—	Dec 31, 2017
2016	$240.12M	−$22.41M	—	—	Dec 31, 2016


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
UnitedHealth Group (UNH)	20.4×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
HCA Healthcare (HCA)	15.8×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Elevance Health (ELV)	12.3×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Ovid Therapeutics (OVID)

P/E Ratio daily chart for Ovid Therapeutics (OVID)

Historical P/E Ratio for Ovid Therapeutics (OVID) from 2016 to 2025

About P/E Ratio at Ovid Therapeutics (OVID)

Ovid Therapeutics P/E Ratio by Year

Ovid Therapeutics P/E Ratio 2021: 1.8×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Ovid Therapeutics (OVID) Key Financials

P/E Ratio daily chart for Ovid Therapeutics (OVID)

Historical P/E Ratio for Ovid Therapeutics (OVID) from 2016 to 2025

About P/E Ratio at Ovid Therapeutics (OVID)

Ovid Therapeutics P/E Ratio by Year

Ovid Therapeutics P/E Ratio 2021: 1.8×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

+What is Ovid Therapeutics's P/E ratio?

+How is the P/E ratio calculated?

+What is the P/E ratio?

+What is a good P/E ratio for Ovid Therapeutics?

+Is Ovid Therapeutics's P/E ratio high or low?

+What is Ovid Therapeutics's historical P/E ratio range?

+What was Ovid Therapeutics's P/E ratio in 2021?

+Why does Ovid Therapeutics's P/E ratio change over time?

Ovid Therapeutics (OVID) Key Financials